OOIR: Observatory of International Research

Papers

(The TQCC of EMBO Molecular Medicine is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Circulating proteomic panels for risk stratification of intracranial aneurysm and its rupture	251
Whole‐brain microscopy reveals distinct temporal and spatial efficacy of anti‐Aβ therapies	171
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer	156
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders	150
Elongator and the role of its subcomplexes in human diseases	135
Targeting the Leukemic stem cell protein machinery by inhibition of mitochondrial pyrimidine synthesis	95
Targeting conformational changes in C‐reactive protein to inhibit pro‐inflammatory actions	79
Depressive patient‐derived GABA interneurons reveal abnormal neural activity associated with HTR2C	76
HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy	76
Targetable Brg1‐CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking	74
A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability	73
TFEB and TFE3 drive kidney cystogenesis and tumorigenesis	64
Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐1	61
IQCN disruption causes fertilization failure and male infertility due to manchette assembly defect	61
Activation of the integrated stress response is a vulnerability for multidrug‐resistant FBXW7 ‐deficient cells	56
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease	55
Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia	55
Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems	53
Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain	53
Eosinophil‐derived IL ‐4 is necessary to establish the inflammatory structure in innate inflammation	53
ASO targeting RBM3 temperature‐controlled poison exon splicing prevents neurodegeneration in vivo	52
Systemic inflammation after stroke: implications for post‐stroke comorbidities	51
Diagnostic biomarkers for active tuberculosis: progress and challenges	51
Shear stress control of vascular leaks and atheromas through Tie2 activation by VE‐PTP sequestration	50
Nerve regeneration by interferon intervention in aging brain	49

Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy	49
Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model	48
Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS‐CoV‐2 mRNA vaccination	48
Functions of double‐negative B cells in autoimmune diseases, infections, and cancers	47
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer	44
Single‐cell profiling of muscle‐infiltrating T cells in idiopathic inflammatory myopathies	44
Macrophage colony‐stimulating factor as a weapon against cytomegalovirus	42
ALX1 ‐related frontonasal dysplasia results from defective neural crest cell development and migration	42
Looking at a baby's heart through the lens of the mother's blood	42
A coordinated multiorgan metabolic response contributes to human mitochondrial myopathy	40
An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS‐CoV ‐2	40
A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis	40
Mitochondrial HSF1 triggers mitochondrial dysfunction and neurodegeneration in Huntington's disease	40
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT	40
Blocking STAT3/5 through direct or upstream kinase targeting in leukemic cutaneous T‐cell lymphoma	39
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer	39
In vivo single‐cell transcriptomics reveal Klebsiella pneumoniae skews lung macrophages to promote infection	39
Mining the bacterial genome to discover new antimicrobial molecules	39
Optimizing the Cas13 antiviral train: cargo and delivery	39
Advances in high‐throughput mass spectrometry in drug discovery	37
The molecular biology of peritoneal metastatic disease	37
A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond	37
Sex differences and risk factors for bleeding in Alagille syndrome	37
Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation	36
Immuno(T)herapy for age‐related diseases	36
X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL	36
AAV induces hepatic necroptosis and carcinoma in diabetic and obese mice dependent on Pebp1 pathway	36
Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis	36
The human host response to monkeypox infection: a proteomic case series study	36
Elucidating effects of environmental exposure using human‐induced pluripotent stem cell disease modeling	36
Functional analysis reveals driver cooperativity and novel mechanisms in endometrial carcinogenesis	35
IL‐27 produced during acute malaria infection regulates Plasmodium‐specific memory CD4⁺ T cells	35
External validity in translational biomedicine: understanding the conditions enabling the cause to have an effect	34
Systemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease	34
Nanobody‐mediated complement activation to kill HIV‐infected cells	34
miR ‐181a/b downregulation: a mutation‐independent therapeutic approach for inherited retinal diseases	33
Trichothiodystrophy‐associated MPLKIP maintains DBR1 levels for proper lariat debranching and ectodermal differentiation	33
Adaptively evolved human oral actinomyces‐sourced defensins show therapeutic potential	33
Molecular and functional properties of human Plasmodium falciparum CSP C‐terminus antibodies	32
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ERα⁺ breast cancer	32
Liver gene therapy with intein‐mediated F8 trans ‐splicing corrects mouse haemophilia A	32
Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection	31
Answer to Gerber et al. “Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy”	31
Dual IRE1 RNase functions dictate glioblastoma development	30
Full eradication of pre‐clinical human papilloma virus‐induced tumors by a lentiviral vaccine	30
Development of allogeneic iPS cell‐based therapy: from bench to bedside	30
NRF3 suppresses squamous carcinogenesis, involving the unfolded protein response regulator HSPA5	30
TAPT1—at the crossroads of extracellular matrix and signaling in Osteogenesis imperfecta	30
A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis	29
Patient‐ and xenograft‐derived organoids recapitulate pediatric brain tumor features and patient treatments	29

A progeroid syndrome caused by a deep intronic variant in TAPT1 is revealed by RNA/SI‐NET sequencing	29
Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma	29
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model	29